Results of CPhI Worldwide 2014: Novalik-Pharm and Pharmplanet Signed International Manufacturing Contracts and Presented Its Own Unique Immunomodulator Beta-Immun

Kyiv, Ukraine, October 24, 2014 --(PR.com)-- On October 7-9, Ukrainian pharmaceutical company Novalik-Pharm and its official distributor Pharmplanet took part in the international exhibition in Paris. This year, CPhI Worldwide celebrates its 25th anniversary. Specifically to this date the organizers arranged a competition "Top 25 Success Stories." According to the decision of the jury, Pharmplanet was included in the list of 25 most successful pharmaceutical world's companies for most dynamic development of the market.

Following the negotiations, Novalik-Pharm and Pharmplanet made contacts with three dozen of foreign companies, some of them are interested in the new company's developments. Four agreements on contract manufacturing of modern drugs under Novalik-Pharm trademark with major European and Asian manufacturers were coordinated and prepared for signing. The work executed on long-term projects for the supply of substances for exclusive distribution and contract manufacturing in demand on Ukrainian pharmaceutical market - new generation antibiotics, antivirals, gastroenterology and oncology drugs in new dosage forms, as well as medical products.

One of the important outcomes was the beginning of cooperation with major Malaysian pharmaceutical company on contract manufacturing modern medicines. One of them is hormonal preparation of a new generation which is 30 times more effective but less toxic than hydrocortisone by the level of anti-inflammatory activity, and don’t possesses mineralocorticoid activity. All the products that company presents to its consumers around the world are manufactured by three pharmaceutical factories, equipped in touch with the state-of-the-art in the field in accordance with the requirements of Good Manufacturing Practice (GMP). A significant part of the products approved by FDA (Food&Drug Administration, USA) and exported to the American market.

Business relationships established with the Taiwanese company on contract manufacturing line of modern antibiotics, unique patches for the treatment of joints and spine diseases, as well as original dressings for wound healing.

As announced earlier, Novalik-Pharm presented to the international community jointly developed with Austrian experts, innovative product Beta-Immun – natural immunomodulator with anti-inflammatory action on the basis of beta-glucans. The drug has a special composition of immunotrophic substance that causes a powerful impact on all parts of the immune system, effectively reduces the severity of inflammation. Beta-Immun aroused a great interest among the European partners. So that companies from Poland and Italy having considered the benefit of the drug decided to explore the possibility of its registration and distribution in the European Union.

In addition to Beta-Immun, European and Asian partners were interested in other original developments of Novalik-Pharm: DryVir for the treatment of herpes, a new combined veinotonic Venoda with a more powerful vienotropic action, natural hepatoprotector Hepanaze with anti-inflammatory and regenerative properties and others. Therefore, in the near future, the appearance of Novalik-Pharm products is expected not only in Ukraine and the CIS countries, but also in the market of Europe and Southeast Asia.

Participation of Ukrainian pharmaceutical companies in the large-scale international exhibitions is further evidence of the active development of the domestic pharmaceutical industry. New knowledge acquired at such events, allow introducing modern world technology that is a key to the creation of improved medicines, and new contacts can develop into strong partnerships.